Lucid Diagnostics Inc. Common Stock Canaccord Genuity's 46th Annual Growth Conference

Yeah. Thanks for having me.

Yeah. Great. So, thanks again. Great to be here. Thank you all for joining. So Lucid Diagnostics is a cancer prevention company. We're in the esophageal cancer space. Esophageal cancer is a very deadly cancer. It's the second most deadly cancer. Highly lethal. It's essentially a death sentence with about an 80% mortality rate. The only way to actually prevent cancer deaths is to actually detect the pre-cancerous conditions. The condition, as Kyle mentioned, called Barrett's Esophagus. When you do that, you can actually do surveillance and treat the late pre-cancerous conditions and actually prevent cancer. So, Lucid has a test called EsoGuard. It's a non-invasive molecular diagnostic test, an NGS test, that is performed on a sample collected in about a 45-second procedure that can be done in an office setting.

That test has extensive clinical evidence base that demonstrates very high negative predictive value at ruling out the precancerous conditions as well as cancer. It is utilized as a triage test in a well-defined population who are at risk of having this precancerous condition. It, as part of a broader program, serves as an early detection program that can prevent esophageal cancer.

Yeah. You know? What's great about this, and why this has been a great opportunity from the beginning, is that the entire paradigm has actually been well established prior to the introduction of this technology.

The target population's been well defined. As I mentioned, the algorithms for surveillance and for treatment of precancer, all of that had been very well established. The standard of care was upper endoscopy. The limitation at that time, over the last couple of decades, and the reason why this cancer still exacts a heavy burden, is that compliance with upper endoscopy, which is established in guidelines, is extremely poor. It's less than 10%, probably closer to zero, actually. That's where we fit in.

That was the one missing link, and as an alternative to standard of care that's underutilized upper endoscopy, we offer this molecular diagnostic test in a non-invasive setting that fills in that final gap.

Yeah. There's really no other effective way to reverse this precancerous condition, Barrett's Esophagus. There is some evidence that PPIs, NEXIUM- Proton pump proton pump inhibitors that can be obtained over the counter that lower acid, have some effect at slowing the progression, but they certainly don't eliminate it, and they don't eliminate the risk of developing later stage pre-cancer dysplasia as well as cancer.

The only opportunity really to prevent this cancer is to identify these patients in the pre-cancerous stage and to do surveillance and do treatment before they develop cancer. I should just note one of the things in our clinical evidence that is unique, it's very hard, it's not very common to have molecular tests that can detect pre-cancerous conditions, particularly early pre-cancerous conditions, at that high level of performance, 99% predictive value. You can detect advanced adenomas at sort of 50% sensitivity and levels like that. But it actually is quite unprecedented to be able to detect this early pre-cancerous condition using a molecular test.